Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 12/20 | 0.69 |
| ▸ | CDC25B | P30305 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9412629 | 0.92 | HCAR3 (0.66) | HCAR3CDC25BHTTMAPTGAA | |
| SCHEMBL11275082 | 0.87 | HCAR3 (0.67) | HCAR3CDC25BHTTMAPTALDH1A1 | |
| SCHEMBL6506088 | 0.86 | KMT2A (0.62) | HCAR3HTTMAPTGAAALDH1A1 | |
| SCHEMBL27268253 | 0.84 | HCAR3 (0.70) | HCAR3CDC25BHTTMAPTALDH1A1 | |
| SCHEMBL11752957 | 0.83 | HCAR3 (0.51) | HCAR3MAPTGAAALDH1A1KMT2A | |
| SCHEMBL12190709 | 0.83 | HCAR3 (0.68) | HCAR3CDC25BHTTMAPTALDH1A1 | |
| SCHEMBL9251399 | 0.83 | HCAR3 (0.64) | HCAR3CDC25BHTTMAPTALDH1A1 | |
| SCHEMBL321911 | 0.82 | HCAR3 (1.00) | HCAR3CDC25BKMT2AMEN1 | |
| SCHEMBL10524428 | 0.81 | HCAR3 (0.76) | HCAR3MAPTGAAALDH1A1KMT2A | |
| SCHEMBL15505486 | 0.81 | TSHR (0.67) | MAPTGAAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| EP-1228060-A1 | ARYLALKANE, ARYLALKENE AND ARYL AZAALKANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032649-A1 | ARYLALKANE, ARYLALKENE AND ARYL AZAALKANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | HCAR3 219/4885CDC25B 2400/4885HTT 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.